FDA Grants Breakthrough Therapy Designation To Novartis' Meningitis B Vaccine

FDA Grants Breakthrough Therapy Designation To Novartis' Meningitis B Vaccine

Novartis Novartis AG in Basel announced early this morning that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation – a rapid development track – for potential approval of Bexsero®, their innovative vaccine against type B …

8
Like
Save

Comments

Write a comment

*